Natco, Ozempic
Here's why Natco Pharma share price gained over 4% on October 7; details
Natco Pharma share rose after the company announced that Mylan Pharmaceuticals Inc & Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic (Semaglutide)
Natco Pharma shares rise 4% on settlement order in US patent case over generic Ozempic
The strong up move was seen in the stock price with the scrip touching the day's high of Rs 1,408.70 per share on the NSE, rising 4 percent.
Mylan and Novo Nordisk settle US generic Ozempic dispute, Natco Pharma poised for market entry
Mylan and Novo Nordisk have reached a confidential settlement over the generic version of Ozempic, with Natco Pharma holding Sole First-to-File (FTF) status for multiple strengths of Ozempic and Wegovy.
Natco Pharma partner Mylan settles patent litigation with Novo Nordisk over generic Ozempic in US
Hyderabad: NATCO Pharma Limited has announced that its partner Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the U.S. patent litigation related to generic
Natco Pharma shares jump 4% amid weak broader markets; here' why
Shares of Natco Pharma Ltd surged nearly 4.35 per cent to Rs 1,413.45 on Monday, commanding a total market capitalization close to Rs 25,000 crore.
Natco Pharma shares gain after settlement in US patent litigation on generic Ozempic
Mylan Pharmaceuticals Inc and Novo Nordisk, the original patent holder for Ozempic, have reached a settlement in the US patent litigation concerning the drug, Natco Pharma informed the stock exchanges in a filing.
Mylan settles patent litigation with Novo Nordisk over generic Ozempic in United States
According to a report by news agency PTI, NATCO and Mylan have partnered for the development of generic Ozempic (Semaglutide) products, the company said in a regulatory filing. Ozempic is a prescription medication patented by Novo Nordisk.
India Infoline1d
Natco Pharma settles US patent case over generic Ozempic
According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.
Hosted on MSN1mon
Natco Pharma share price hits 52-week high after 90% rally year to date. Buy, Sell or Hold?
The strong performance in the US markets is driving the gains for Natco Pharma share price. Natco Pharma reported total consolidated revenues at ₹1411 crore grew 21.5% year on year. The ...
Zee Business4mon
Natco Pharma rises nearly 2% after mid-cap firm submits application for Rimegepant Sulfate tablets to US FDA
Natco Pharma shares that closed trading at Rs 1,020.15 each a day ... Rimegepant Sulfate tablets are marketed in the United States (US) by Pfizer Inc. under the brand name NURTEC ODT®, the ...
India Infoline5d
Natco Pharma Ltd Company Summary
In 2007, Natco Pharma launched its first abbreviated new drug application (ANDA) in the US market. During the year, the company acquired Savemart Pharmacy in USA.In 2008, Natco Pharma ...
Trade Spotlight: How should you trade Bajaj Finance, Nestle, Indian Hotels, Natco Pharma, Havells and others on Thursday?
The Nifty 50 is expected to remain rangebound before moving in a firm direction. Below are some trading ideas for the near ...
Mint1mon
Top Stock Recommendations: Dharmesh Shah of ICICI Securities suggests buying Kajaria Ceramics, and Natco Pharma today
Markets are expected to be influenced by two factors: the US presidential election result ... d) Sectorally, Pharma, FMCG, IT are expected to relatively perform better. PSU banks appear oversold ...